Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.
You may also be interested in...
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.
Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.
Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: